Samarkandi Abdulhamid H, Shaikh Mussarat A, Ahmad Rana A, Alammar Ahmed Y
Department of Anesthesia, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Saudi Med J. 2004 Nov;25(11):1636-9.
The purpose of this study is to determine whether a single dose of dexamethasone 0.5mg/kg administered before surgery could decrease post operative vomiting and pain and improves oral intake in the first 24-hours after pediatric tonsillectomy procedures.
It is a randomized, double blind, placebo controlled study. Sixty children age 2-12-years ASA 1 and 11 were scheduled for tonsillectomy, dexamethasone (n=29) and control group (n=31) were enrolled in the study. Dexamethasone group received 0.5mg/kg intravenous dexamethasone and control group received saline at the time of induction. The anesthetic regimen and surgical procedures were standardized for all patients. All patients were observed in post anesthesia care unit (PACU) and ward for post operative vomiting, pain, need for rescue antiemetic or analgesia and time for first oral intake for 24-hours.
Data from 60 patients were analyzed. The overall incidence of early as well as late vomiting was significantly less in dexamethasone as compared to control group (37% versus 74% P=0.016), overall incidence of retching was 29% in control and 3.4% in dexamethasone (p=0.008). Vomiting once or more than once was significantly high in control as compared to dexamethasone group. The need for rescue antiemetic, the time to first oral intake and analgesic requirements did not show any significant difference in both groups.
Dexamethasone is considered safe and there was no adverse effects associated with a single dose of dexamethasone. Although the need for rescue antiemetic, time to oral intake and analgesia requirements in both groups were not significant, however, we found that dexamethasone does have antiemetic properties as overall incidence of retching and vomiting was significantly less in dexamethasone group as compared to control group in children who underwent tonsillectomy.
本研究旨在确定术前单次给予0.5mg/kg地塞米松是否能减少小儿扁桃体切除术后的呕吐和疼痛,并改善术后24小时内的口服摄入量。
这是一项随机、双盲、安慰剂对照研究。60名年龄在2至12岁、美国麻醉医师协会(ASA)分级为1级和2级的儿童计划进行扁桃体切除术,地塞米松组(n = 29)和对照组(n = 31)纳入研究。地塞米松组在诱导时静脉注射0.5mg/kg地塞米松,对照组注射生理盐水。所有患者的麻醉方案和手术程序均标准化。所有患者在麻醉后护理单元(PACU)和病房观察术后呕吐、疼痛、是否需要抢救性止吐或镇痛以及术后24小时首次口服摄入的时间。
对60例患者的数据进行了分析。与对照组相比,地塞米松组早期和晚期呕吐的总体发生率显著降低(37%对74%,P = 0.016),对照组干呕的总体发生率为29%,地塞米松组为3.4%(P = 0.008)。与地塞米松组相比,对照组呕吐一次或多次的情况显著更高。两组在抢救性止吐的需求、首次口服摄入的时间和镇痛需求方面均未显示出任何显著差异。
地塞米松被认为是安全的,单次剂量的地塞米松未产生不良反应。尽管两组在抢救性止吐的需求、口服摄入的时间和镇痛需求方面均无显著差异,但我们发现地塞米松确实具有止吐特性,因为在接受扁桃体切除术的儿童中,与对照组相比,地塞米松组干呕和呕吐的总体发生率显著更低。